Nobivac® DHPPi

Nobivac® DHPPi

Vaccine for distemper, hepatitis (canine adenovirus), canine parvovirus and canine parainfluenza(Dogs)

Categories , Tags , ,

Description

Nobivac DHPPi

Nobivac DHPPi provides immunisation to dogs for distemper, hepatitis (canine adenovirus), canine parvovirus and canine parainfluenza and is typically given in combination with a Nobivac leptospirosis vaccine (Nobivac Lepto2 or L4). It is recommended that puppies may be immunised from 6 weeks of age, 2-4 weeks apart, with a second dose from 10 weeks of age. Onset of immunity is one week after the second vaccine. In dogs over 10 weeks of age a single dose is likely to be sufficient to immunise.

Immunity provided against these core diseases is long lasting, with a minimum duration of immunity and recommended revaccination interval of 3 years. An annual health check and vaccination against canine leptospirosis is still recommended for all dogs.

Presentation

Off-white or cream-colored lyophilisate for suspension for injection

Active ingredients

Nobivac DHPPi contains live, attenuated, freeze dried canine distemper virus, canine adenovirus-2 (CAV2), canine parvovirus and canine parainfluenza virus.

Each dose of 1 ml contains:

Live canine distemper virus (CDV), strain Onderstepoort ≥ 104.0 TCID50*

Live canine adenovirus type 2 (CAV2), strain Manhattan LPV3 ≥ 104.0 TCID50*

Live canine parvovirus (CPV), strain 154 ≥ 107.0 TCID50*

Live canine parainfluenza virus (CPi), strain Cornell ≥ 105.5 TCID50*

TCID50*= Median Tissue Culture Infective Dose

Target species

Dog

Indications for use

Nobivac DHPPi is indicated for active immunisation of dogs to:

  • Prevent mortality and clinical signs caused by canine distemper virus infection
  • Reduce clinical signs of infectious hepatitis and viral excretion due to canine adenovirus type 1 infection
  • Prevent mortality, clinical signs and viral excretion following canine parvovirus infection
  • Reduce clinical signs and viral excretion caused by canine parainfluenza virus infection
  • To reduce clinical signs of respiratory disease and viral excretion following adenovirus type 2 infection

Packaging

Nobivac DHPPi is presented in APET-Plastic trays containing 10 or 50 single dose vials. Nobivac Solvent is packaged separately.

Legal category

MSD Product

Persian catalogue